| Drug General Information |
| Drug ID |
D0V2JK
|
| Former ID |
DNAP001526
|
| Drug Name |
Nomegestrol acetate
|
| Synonyms |
Lutenyl (TN)
|
| Drug Type |
Small molecular drug
|
| Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Approved |
[1],
[2],
[3]
|
|---|
| Company |
Theramex
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C23H30O4
|
| Canonical SMILES |
CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4C1=CC(=O)CC4
|
| InChI |
1S/C23H30O4/c1-13-11-20-18(17-6-5-16(26)12-19(13)17)7-9-22(4)21(20)8-10-23(22,14(2)24)27-15(3)25/h11-12,17-18,20-21H,5-10H2,1-4H3/t17-,18-,20-,21+,22+,23+/m1/s1
|
| InChIKey |
IIVBFTNIGYRNQY-YQLZSBIMSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
10224953, 12012866, 14779536, 14901932, 44422592, 47437897, 47957450, 48332093, 49699259, 49998341, 50123955, 53789425, 56463139, 57335005, 71825008, 74598451, 85787546, 92719115, 96024968, 103097908, 104405391, 121363742, 124758661, 124799569, 126621067, 126648896, 126665670, 135047883, 137267779, 152035982, 160687877, 162222952, 175267383, 175612115, 179150722, 184546245, 184546356, 196110831, 211535868, 223675023, 226423291, 244160803, 252355210, 252423456
|
| SuperDrug ATC ID |
G03DB04
|
| Target and Pathway |
| Target(s) |
Estrogen receptor |
Target Info |
Modulator |
[1],
[2],
[3]
|
|---|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Pancreatic Cancer Pathway
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells. J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):111-22. |
|---|
| REF 2 | Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61. |
|---|
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
